시간 외 거래: 6.81 -0.21 -2.99%

Cybin Inc (CYBN)

개요 뉴스 가격 이력 토론 예측

Cybin Inc 주식(CYBN)의 최신 뉴스

Cybin Inc (CYBN)

Cybin Inc 주식(CYBN)의 최신 뉴스

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Acce - GuruFocus

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics | CYBN Stock News - GuruFocus

Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics - Business Wire

Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 - MSN

(CYBN) Investment Analysis - news.stocktradersdaily.com

Cybin, Inc: Covering All Bases as Commercialization Preparations Continue - Smartkarma

Cboe Canada Single Security - Cboe Global Markets

Cybin partners with Thermo Fisher for Phase 3 drug production By Investing.com - Investing.com Nigeria

Thermo Fisher Scientific (NYSE:TMO) Partners With Cybin For Phase 3 Depression Treatment - simplywall.st

Cybin (CYBN) Collaborates with Thermo Fisher for Phase 3 Development | CYBN Stock News - GuruFocus

CYBN Gains on Thermo Fisher Partnership for CYB003 Production - GuruFocus

AGC Bio secures lentiviral contract; Thermo Fisher to make Cybin asset - Endpoints News

Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 (CYBN:NYSE) - Seeking Alpha

Cybin Says Thermo Fisher Scientific to Offer US-Based Manufacturing for Its Depressive Disorder Program - marketscreener.com

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Man - GuruFocus

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder | CYBN Stock News - GuruFocus

Cybin partners with Thermo Fisher for Phase 3 drug production - Investing.com

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder | FinancialContent - FinancialContent

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase - BioSpace

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase | CYBN Stock News - GuruFocus

Cybin CEO to Speak at Healthcare Showcase, Highlighting Innovations in Mental Health Treatment - TipRanks

Cybin (OTCMKTS:CYBN) Shares Down 0.5% – Time to Sell? - Defense World

Cybin stock price target cut to $150 at H.C. Wainwright - MSN

Cybin secures new patent for depression treatment drug - Investing.com

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder - BioSpace

Cybin (CYBN) Secures U.S. Patent for CYB003 Program | CYBN Stock News - GuruFocus

Cybin secures new patent for depression treatment drug By Investing.com - Investing.com Nigeria

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder | CYBN Stock News - GuruFocus

Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder - marketscreener.com

Trading (CYBN) With Integrated Risk Controls - news.stocktradersdaily.com

Cybin wins new Buy from Guggenheim: potential to challenge J&J’s Spravato cited - MSN

Marshall Wace LLP Makes New Investment in Cybin Inc. (NYSE:CYBN) - Defense World

Should You Buy, Sell, or Hold AppLovin Stock Before Q1 Earnings? - The Globe and Mail

Psychedelic drug developer Cybin partners with Osmind - MSN

Cybin (CYBN) Gets a Buy from H.C. Wainwright - The Globe and Mail

Cybin to Participate at the 28th Annual Milken Institute Global Conference | CYBN Stock News - GuruFocus

Cybin to Participate at the 28th Annual Milken Institute Global Conference - Bluefield Daily Telegraph

ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRI - The Globe and Mail

Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com

Cybin (NYSE:CYBN) Trading Up 2.9% – Here’s What Happened - Defense World

Cybin advances Phase 3 trial for depression treatment By Investing.com - Investing.com South Africa

Cybin Announces Additional Strategic Clinical Site Partnerships - GuruFocus

Cybin (CYBN) Expands Strategic Partnerships for Phase 3 MDD Prog - GuruFocus

Cybin Expands Strategic Partnerships for Phase 3 MDD Treatment Trials - TipRanks

Cybin (CYBN) Expands Strategic Partnerships for Phase 3 MDD Program | CYBN Stock News - GuruFocus

Cybin advances Phase 3 trial for depression treatment - Investing.com

CYBN과 유사한 종목